STOCK TITAN

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced the grant of stock options for 23,200 shares and 16,000 restricted stock units (RSUs) to seven new employees as of October 31, 2022. These awards were made under the 2022 Inducement Stock Incentive Plan as an incentive for new hires in line with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $4.76 per share and will vest over four years, while RSUs will also vest over the same period. Both awards include conditions related to employment status and change in control provisions.

Positive
  • Grant of stock options and RSUs as part of employee incentivization, potentially enhancing talent acquisition.
  • Stock options priced at $4.76, the closing price on the grant date, reflects current market rates.
Negative
  • None.

NEWTON, Mass., Nov. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted stock options to purchase an aggregate of 23,200 shares of Karyopharm's common stock and an aggregate of 16,000 restricted stock units (RSUs) to seven newly-hired employees. These equity awards were granted as of October 31, 2022 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Each of the stock options has an exercise price of $4.76 per share, the closing price of Karyopharm's common stock on October 31, 2022. Each stock option will vest over four years, with 25% of the total number of shares underlying the stock option vesting on the one-year anniversary of the applicable employee's employment commencement date and 1/48th of the total number of shares vesting monthly thereafter. Each RSU award will vest over four years, with 25% percent of the shares underlying the RSU award vesting on each of the four consecutive anniversaries of the applicable employee's employment commencement date. The vesting of each inducement award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. In addition, each stock option and RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the applicable stock option or RSU agreement).

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China, Singapore, Canada, Israel, South Korea and Australia. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301665295.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What was announced by Karyopharm Therapeutics on November 1, 2022?

Karyopharm announced the grant of stock options and restricted stock units to new employees.

How many shares were included in the stock option grant by Karyopharm?

The grant included stock options for an aggregate of 23,200 shares.

What is the exercise price for the stock options granted by Karyopharm?

The exercise price for the stock options is $4.76 per share.

What is the vesting schedule for the stock options and RSUs granted by Karyopharm?

Both stock options and RSUs vest over four years with specific annual and monthly conditions.

Under which plan did Karyopharm grant the stock options and RSUs?

The grants were made under the 2022 Inducement Stock Incentive Plan.

Karyopharm Therapeutics Inc.

NASDAQ:KPTI

KPTI Rankings

KPTI Latest News

KPTI Stock Data

82.52M
117.36M
6.15%
50%
15.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEWTON